Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877251345162 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Wiesław J Cubała und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland. Hauptthemen laut MEDLINE: Piperidines, Urea, Neurodegenerative Diseases. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ACADIA Pharmaceuticals.
Abstract (Originalsprache)
Background
An 8-week, phase 3b, randomized, placebo-controlled trial demonstrated that pimavanserin, a selective 5HT 2A inverse agonist, is generally well tolerated in elderly patients with neuropsychiatric symptoms related to neurodegenerative disease (NDD).
Objective
This open-label extension (OLE) study assessed the long-term safety and tolerability of pimavanserin.
Methods
Patients from the antecedent double-blind (DB) trial who were treated with oral pimavanserin (34 mg/day) or placebo were enrolled. The safety analysis population included all patients who received ≥1 dose of pimavanserin. The primary endpoint was treatment-emergent adverse events (TEAEs). Exploratory endpoints included change from baseline in Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A), Mini-Mental State Examination (MMSE), Clinical Global Impression-Severity (CGI-S), EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and Sleep Disorders Inventory (SDI) scores.
Results
Patients (N = 595; mean age, 72.2 years) received pimavanserin treatment (mean exposure, 312.4 days). Most patients (95.3%) had dementia (68.7% of whom had Alzheimer's disease), and 70.6% were concomitantly treated with anti-dementia drugs. TEAEs occurred in 238 (40.0%) patients, and 37 (6.2%) had a serious TEAE; 1 (0.2%) was pimavanserin-related. TEAEs resulted in treatment discontinuation in 39 (6.6%) patients. Fatal TEAEs occurred in 11 (1.8%) patients (none considered related to pimavanserin). The mean (standard error) change from DB baseline to OLE Week 52 in MMSE, ESRS-A, CGI-S, EQ-5D-5L, and SDI scores was +0.9 (0.21), −0.3 (0.22), −1.0 (0.05), + 10.7 (0.87), and −0.9 (0.07), respectively. No patients reported suicidal behavior.
Conclusions
Pimavanserin was generally well tolerated in frail older adults and elderly patients with neuropsychiatric symptoms related to NDD for up to 52 weeks of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
- Acadia Pharmaceuticals Inc., San Diego, CA, USA.
- ATP Clinical Research, Department of Psychiatry and Neuroscience, University of California at Riverside, Riverside, CA, USA.
- Acadia Pharmaceuticals Inc., Princeton, NJ, USA.
ORCID-Profile: Wiesław J Cubała, Ana Berrio, Gustavo Alva, Lambros Chrones, Sanjeev Pathak
Förderung
- ACADIA Pharmaceuticals
Zitieren
APA
Cubała, W. J., Berrio, A., Chi-Burris, K., Alva, G., Chrones, L., & Pathak, S. (2025). Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251345162
Vancouver
Cubała WJ, Berrio A, Chi-Burris K, Alva G, Chrones L, Pathak S. Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251345162
BibTeX
@article{Cubaa2025,
author = {Cubała, Wiesław J and Berrio, Ana and Chi-Burris, Katherine and Alva, Gustavo and Chrones, Lambros and Pathak, Sanjeev},
title = {Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877251345162}
}
EUVIMED